Drug class
Janus kinase 2 (JAK2) inhibitor; targeted antineoplastic kinase inhibitor
Mechanism of action
Inhibits JAK2, including wild-type and mutationally activated forms, and has activity against FLT3. This reduces JAK-STAT signalling implicated in myeloproliferative neoplasm pathogenesis.
General use cases
- Treatment of adults with intermediate-2 or high-risk primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera or post-essential thrombocythaemia) under the current product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
